 |
|
Attention: Extra-hepatic manifestation of hepatitis C virus infection
January 17, 2008In 1994, the team of Tchernev and Petrova from Alexandrovska Hospital in Sofia examined a female patient with liver cirrhosis caused by chronic Hepatitis C virus (HCV). They were intrigued by the patient's many extra-hepatic manifestations -- vascular lesions on the lower limbs, acute pain in the joints, intense tingling of the fingers, and extreme labor-impairing fatigue. They were also intrigued by the presence of cryoglobulins in the patient's blood. Two years later, the patient developed enlarged lymph nodes on the neck. When one of the nodes was histologically tested, the patient was found to have lymphoma.
This case spurred the interest of the investigators in the extra-hepatic manifestations and complications of HCV infection, and for over a decade they studied the links between HCV infection, cryoglobulinemia, and lymphoma.
A research article published on December 28, 2007 in the World Journal of Gastroenterology addresses this problem. In a study of 136 Bulgarian patients with HCV, the team of Tchernev and Petrova found 76.5% of the patients had extra-hepatic manifestations. Common manifestations were fatigue (59.6%), renal impairment (25%), type 2 diabetes (22.8%), paresthesia (19.9%), arthralgia (18.4%), and purpura predominantly of the lower limbs (17.6%). Over 37% of the patients had cryoglobulins, and 8.8% had B-cell lymphoma.
The study found positive links between the presence of extra-hepatic manifestations and age, female gender, duration of the infection, infection by transfusion of blood and blood products, and extensive liver fibrosis. Therefore, elderly women with chronic HCV and advanced liver fibrosis, who were infected by transfusion during childbirth, are at the highest risk of developing extra-hepatic manifestations of HCV infection.
The study also showed most extra-hepatic manifestations of HCV infection are associated with the presence of cryoglobulins. In particular, the risks of developing B-cell non-Hodgkin lymphoma are much higher in cryoglobulin-positive than in cryoglobulin-negative patients. In the study, 17.6% of cryoglobulin-positive patients had lymphoma, whereas only 3.5% of cryoglobulin-negative patients did.
Given the prevalence of HCV around the world, it is important for physicians to recognize the extra-hepatic signs and symptoms of HCV infection. Patients who exhibit such manifestations should be tested for HCV infection. This can lead to prompt diagnosis and effective treatment of the infection before the development of cryoglobulinemia, when treatment gives poor results or is ineffective.
World Journal of Gastroenterology
The study found positive links between the presence of extra-hepatic manifestations and age, female gender, duration of the infection, infection by transfusion of blood and blood products, and extensive liver fibrosis. Therefore, elderly women with chronic HCV and advanced liver fibrosis, who were infected by transfusion during childbirth, are at the highest risk of developing extra-hepatic manifestations of HCV infection.
The study also showed most extra-hepatic manifestations of HCV infection are associated with the presence of cryoglobulins. In particular, the risks of developing B-cell non-Hodgkin lymphoma are much higher in cryoglobulin-positive than in cryoglobulin-negative patients. In the study, 17.6% of cryoglobulin-positive patients had lymphoma, whereas only 3.5% of cryoglobulin-negative patients did.
Given the prevalence of HCV around the world, it is important for physicians to recognize the extra-hepatic signs and symptoms of HCV infection. Patients who exhibit such manifestations should be tested for HCV infection. This can lead to prompt diagnosis and effective treatment of the infection before the development of cryoglobulinemia, when treatment gives poor results or is ineffective.
World Journal of Gastroenterology
Hcv Infection Current Events and Hcv Infection News RSSIs endotoxin receptor CD14 rs2569190/C-159T gene correlated with chronic hepatitis C?
It is still unknown why the natural history of chronic disease caused by hepatitis C virus (HCV), which currently infects 3% of the world's population, varies from mild in some patients to rapidly progressing in others.
The hepatitis healing power of blueberry leaves
A chemical found in blueberry leaves has shown a strong effect in blocking the replication of the Hepatitis C virus, opening up a new avenue for treating chronic HCV infections, which affect 200 million people worldwide and can eventually lead to cirrhosis and liver cancer.
First human gets new antibody aimed at hepatitis C virus
Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).
A potential targeting gene therapy for developing HCV
Gene therapy has emerged as a novel approach to combat HCV infection in the last few years.
NEJM Study Points to New Era in Hepatitis C Treatment
For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.
Hyperferritinemia is another surrogate marker of advanced liver disease
High serum ferritin, being a hallmark of hereditary hemochromatosis , is frequently found in chronic hepatitis C, alcoholic or non-alcoholic steatohepatitis and non-alcoholic fatty liver disease patients.
Novel antibody prevents infection by hepatitis C virus
Taking aim at a leading cause of liver failure in the United States, a team of scientists at the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) has developed a human monoclonal antibody that neutralizes the Hepatitis C virus (HCV).
First evidence for DNA-based vaccination against chronic hepatitis C
The first-proof-of-concept for a DNA-based therapeutic vaccination against chronic hepatitis C was announced today at EASL 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark.
2-day results predict ultimate response to therapy in chronic hepatitis C
A new study suggests that previously noted low rates of successful hepatitis C virus (HCV) therapy in African Americans are in large part due to very early differences in the antiviral activity induced by interferon.
Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment
New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.
More Hcv Infection Current Events and Hcv Infection News Articles
|
Hold Off on Treating the Very Young for HCV. (Most will clear Infection by 18 Months).(hepatitis C): An article from: Pediatric News by Sally Koch Kubetin (Author) This digital document is an article from Pediatric News, published by International Medical News Group on November 1, 2001. The length of the article is 470 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Hold Off on Treating the Very Young for HCV. (Most will clear Infection by 18 Months).(hepatitis C) Author: Sally Koch Kubetin Publication: Pediatric News (Magazine/Journal) Date: November 1, 2001 Publisher: International Medical News Group Volume: 35 Issue: 11 Page: 16(1) Distributed by Thomson... | |
 |
The HIV / HCV Co-Infection Awareness Ribbon Mouse Pad by MyHeritageWear.com The HIV / HCV Co-Infection Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the HIV / HCV Co-Infection Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your HIV / HCV Co-Infection Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
EPA approved - Protex Disinfectant Spray Bottle, 12 oz. Efective against MRSA, E-coli, influenza, H1N1, Herpes, HBV, VISA, VRE, HCV, HIV. by Parker Labs A powerful one-step disinfectant effective against a broad spectrum of pathogens, including MRSA, HIV, Staph and many others. Useful in disinfecting ultrasound transducers, probes, mammography compressor plates and other hard nonporous, non-surgical surfaces. Protex is an EPA approved, one-step spray that effectively kills a wide range of bateria, viruses, and fungi including: MRSA, E-coli, influenza, H1N1, Herpes, HBV, VISA, VRE, HCV, HIV Salmonella and Norwalk Virus. |
 |
Expert Opinions on Contemporary Clinical Issues in Hepatitis C (Part One) (NCME Video 760) Also With: Network For Continuing Medical Education (Primary Contributor), Willis C. Maddrey (Primary Contributor), Eugene R. Schiff (Primary Contributor) Important lessons regarding relapse and its prevention and treatment were learned from managing chronic hepatitis C virus (HCV) infections with monotherapy. It now appears that some of these lessons may be applicable with combination therapy. In addition, many clinicians and investigators now question whether these other populations, such as interferon nonresponders, might also benefit from combination therapy. In Read more Important lessons regarding relapse and its prevention and treatment were learned from managing chronic hepatitis C virus (HCV) infections with monotherapy. It now appears that some of these lessons may be applicable with combination therapy. In addition, many clinicians and investigators now question whether these other populations, such as interferon nonresponders,... |
|
Combination therapy for mild, chronic HCV. (hepatitis C virus infection).(Bottom Line): An article from: Internal Medicine News by Jeff Evans (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on October 1, 2003. The length of the article is 419 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Combination therapy for mild, chronic HCV. (hepatitis C virus infection).(Bottom Line) Author: Jeff Evans Publication: Internal Medicine News (Magazine/Journal) Date: October 1, 2003 Publisher: International Medical News Group Volume: 36 Issue: 19 Page: 69(1) Distributed by Thomson... | |
 |
Hepatitis Annual Update 2004 - Collection of Review Articles Addressing Many of the Most Important Clinical Issues Faced By Physicians by MD John P. Phair (Author) For the 2004 edition of the Hepatitis Annual Update, we are delighted to present a wonderful collection of review articles addressing many of the most important clinical issues faced by physicians who treat patients with hepatitis. Topics covered: 1) Immunopathogenesis of Acute Hepatitis B and Hepatitis C 2) HBV Treatment Guidelines: Questions and Controversies 3) New Data on Hepatitis B Virus Treatment 4) Natural History, Diagnostics, and Clinical Profiles of Persons With Chronic Hepatitis B 5) World Epidemiology of Hepatitis C 6) Hepatitis C Treatment: Today and Tomorrow 7) Impact of Nonalcoholic Fatty Liver Disease on Hepatitis C 8) Cirrhosis and Beyond 9) Hepatocellular Carcinoma 10) HIV Coinfection 11) Drug Induced Hepatotoxicity: 2004 |
|
Double jeopardy: The HIV/HCV co-infection handbook by Lillian Thiemann (Author) | |
|
My personal experience in being HCV/HIV co-infected & how I cured hepatitis C.(Essays): An article from: Research Initiative/Treatment Action! by Jules Levin (Author) This digital document is an article from Research Initiative/Treatment Action!, published by The Center for AIDS: Hope & Remembrance Project on September 22, 2004. The length of the article is 1511 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: My personal experience in being HCV/HIV co-infected & how I cured hepatitis C.(Essays) Author: Jules Levin Publication: Research Initiative/Treatment Action! (Refereed) Date: September 22, 2004 Publisher: The Center for AIDS: Hope & Remembrance Project Volume: 10 Issue: 2 Page: 28(3) Distributed by Thomson... | |
|
Cutaneous Manifestations Of HIV and HCV.: An article from: Dermatology Nursing by Julia R. Nunley (Author) This digital document is an article from Dermatology Nursing, published by Jannetti Publications, Inc. on June 1, 2000. The length of the article is 6291 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. From the author: Human immunodefiency virus (HIV) and hepatitis C virus (HCV) infections have had major effects on the field of medicine over the past 2 decades. Dermatologic manifestations are common and may be the presenting complaint in either disease. Clinicians should be aware of these cutaneous conditions so that the underlying disease may be properly diagnosed. Citation Details Title:... | |
|
Daily Interferon, Ribavirin preferred Therapy in HIV/HCV Coinfections. (Better Than Thrice-Weekly Therapy).: An article from: Internal Medicine News by Bruce Jancin (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on January 1, 2002. The length of the article is 770 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Daily Interferon, Ribavirin preferred Therapy in HIV/HCV Coinfections. (Better Than Thrice-Weekly Therapy). Author: Bruce Jancin Publication: Internal Medicine News (Magazine/Journal) Date: January 1, 2002 Publisher: International Medical News Group Volume: 35 Issue: 1 Page: 12(1) Distributed by Thomson... |
| © 2009 BrightSurf.com |